Wenhui Li

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 8

Top Topics

Breast Cancer Cells

Endoplasmic Reticulum

Top Venues

Cell death & disease

Journal of personalized medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Tinglin Yang, Wenhui Li, Jun Zhou, Ming Xu, Ziwei Huang, Jie Ming, Tao Huang
A novel bystander effect in tamoxifen treatment: PPIB derived from ER+ cells attenuates ER- cells via endoplasmic reticulum stress-induced apoptosis. Cell death & disease 15 (2) (2024)
Tinglin Yang, Wenhui Li, Jun Zhou, Ming Xu, Ziwei Huang, Jie Ming, Tao Huang
A novel bystander effect in tamoxifen treatment: PPIB derived from ER+ cells attenuates ER- cells via endoplasmic reticulum stress-induced apoptosis. Cell death & disease 15 (2) (2024)
Tinglin Yang, Wenhui Li, Jun Zhou, Ming Xu, Ziwei Huang, Jie Ming, Tao Huang
A novel bystander effect in tamoxifen treatment: PPIB derived from ER+ cells attenuates ER- cells via endoplasmic reticulum stress-induced apoptosis. Cell death & disease 15 (2) (2024)
Tinglin Yang, Wenhui Li, Jun Zhou, Ming Xu, Ziwei Huang, Jie Ming, Tao Huang
A novel bystander effect in tamoxifen treatment: PPIB derived from ER+ cells attenuates ER- cells via endoplasmic reticulum stress-induced apoptosis. Cell death & disease 15 (2) (2024)
Tinglin Yang, Wenhui Li, Jun Zhou, Ming Xu, Ziwei Huang, Jie Ming, Tao Huang
A novel bystander effect in tamoxifen treatment: PPIB derived from ER+ cells attenuates ER- cells via endoplasmic reticulum stress-induced apoptosis. Cell death & disease 15 (2) (2024)
Tinglin Yang, Wenhui Li, Tao Huang, Jun Zhou
Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer. Journal of personalized medicine 13 (3) (2023)
Tinglin Yang, Wenhui Li, Tao Huang, Jun Zhou
Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer. Journal of personalized medicine 13 (3) (2023)
Tinglin Yang, Wenhui Li, Tao Huang, Jun Zhou
Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer. Journal of personalized medicine 13 (3) (2023)